Published in Lancet on February 26, 2014
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
Genomic spectra of biliary tract cancer. Nat Genet (2015) 1.58
Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis (2014) 1.28
Cancer review: Cholangiocarcinoma. J Carcinog (2015) 1.17
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist (2016) 1.09
Liver transplantation for intrahepatic cholangiocarcinoma. Lancet (2014) 1.07
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02
FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget (2015) 1.01
Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. Am J Gastroenterol (2016) 1.00
Autophagy may promote carcinoma cell invasion and correlate with poor prognosis in cholangiocarcinoma. Int J Clin Exp Pathol (2014) 0.89
Multicentric recurrence of intraductal papillary neoplasms of bile duct in the remnant intrahepatic bile duct after curative resection. Int J Surg Case Rep (2015) 0.88
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep (2015) 0.87
Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) (2016) 0.87
Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol (2016) 0.86
Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep (2016) 0.83
Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. Oncotarget (2014) 0.83
Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. BMC Cancer (2015) 0.81
Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma. Sci Rep (2015) 0.81
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett (2016) 0.81
A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma. BMC Cancer (2016) 0.81
Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. Exp Mol Pathol (2014) 0.81
The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget (2015) 0.81
Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol (2015) 0.81
Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol (2016) 0.81
Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. Oncotarget (2016) 0.80
MicroRNAs in Cholangiopathies. Curr Pathobiol Rep (2014) 0.80
Treatment of Leptomeningeal Carcinomatosis in a Patient With Metastatic Cholangiocarcinoma. ACG Case Rep J (2014) 0.80
Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget (2015) 0.80
MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. J Clin Med (2015) 0.79
Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Onco Targets Ther (2015) 0.79
Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: the OASIS-CANCER Study. J Stroke (2016) 0.79
Suppression of Ov-grn-1 encoding granulin of Opisthorchis viverrini inhibits proliferation of biliary epithelial cells. Exp Parasitol (2014) 0.79
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol (2015) 0.79
Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. Liver Cancer (2015) 0.79
HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma. Oncol Rep (2015) 0.79
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol (2015) 0.78
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology (2016) 0.78
MicroRNAs and benign biliary tract diseases. Semin Liver Dis (2015) 0.78
Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer (2015) 0.78
Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro. PLoS One (2015) 0.78
Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77
A Comprehensive Public Health Conceptual Framework and Strategy to Effectively Combat Cholangiocarcinoma in Thailand. PLoS Negl Trop Dis (2016) 0.77
14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/snail signaling pathway. Oncotarget (2016) 0.77
IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle (2014) 0.77
WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma. Dig Dis Sci (2016) 0.77
Retinal and vitreous metastases from hepatocholangiocarcinoma. BMC Cancer (2017) 0.76
The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. PLoS One (2015) 0.76
Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. Drug Des Devel Ther (2015) 0.76
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov (2016) 0.76
Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med (2016) 0.76
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol (2017) 0.76
Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition. Oncol Rep (2015) 0.76
Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. Am J Gastroenterol (2015) 0.76
Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. Int J Mol Sci (2016) 0.76
Guggulsterone-induced apoptosis in cholangiocarcinoma cells through ROS/JNK signaling pathway. Am J Cancer Res (2016) 0.75
Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int (2016) 0.75
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS One (2015) 0.75
Role of circulating microRNAs in liver diseases. World J Hepatol (2017) 0.75
Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg (2016) 0.75
Isocitrate Dehydrogenase Genes. Dtsch Arztebl Int (2015) 0.75
Expression of Molecular Differentiation Markers Does Not Correlate with Histological Differentiation Grade in Intrahepatic Cholangiocarcinoma. PLoS One (2016) 0.75
Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther (2017) 0.75
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol (2017) 0.75
The real-time dynamic monitoring of microRNA function in cholangiocarcinoma. PLoS One (2014) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol (2016) 0.75
Building a staircase to precision medicine for biliary tract cancer. Nat Genet (2015) 0.75
Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis. HPB (Oxford) (2016) 0.75
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. Am J Pathol (2017) 0.75
Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Res Treat (2016) 0.75
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis (2016) 0.75
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer (2016) 0.75
Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis. Cancer Gene Ther (2016) 0.75
Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma. J Gastrointest Oncol (2016) 0.75
Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. Clin Epigenetics (2016) 0.75
Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis. PLoS One (2016) 0.75
Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Sci Rep (2016) 0.75
Biliary tract cancer stem cells - translational options and challenges. World J Gastroenterol (2017) 0.75
Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma. World J Gastroenterol (2017) 0.75
Individualized preoperative planning using three-dimensional modeling for Bismuth and Corlette type III hilar cholangiocarcinoma. World J Surg Oncol (2016) 0.75
A case of distal extrahepatic cholangiocarcinoma with two positive resection margins. Oncol Lett (2016) 0.75
Unusual presentation of a distal cholangiocarcinoma. Clin Case Rep (2015) 0.75
Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified? Clin Liver Dis (Hoboken) (2016) 0.75
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. World J Hepatol (2017) 0.75
Sarcopenia as a prognostic factor in hepatolithiasis-associated intrahepatic cholangiocarcinoma patients following hepatectomy: a retrospective study. Int J Clin Exp Med (2015) 0.75
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol (2016) 0.75
Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. Carcinogenesis (2016) 0.75
Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget (2016) 0.75
Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.75
Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor δ (PPARδ) in human cholangiocarcinoma. Dig Liver Dis (2014) 0.75
Liver transplantation for intrahepatic cholangiocarcinoma--Authors' reply. Lancet (2014) 0.75
Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget (2016) 0.75
Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography. Endosc Int Open (2016) 0.75
Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol (2017) 0.75
Overexpression of the X-linked ribosomal protein S4 predicts poor prognosis in patients with intrahepatic cholangiocarcinoma. Oncol Lett (2017) 0.75
Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma. ESMO Open (2017) 0.75
Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. World J Surg (2017) 0.75
Targeted therapy in biliary tract cancers-current limitations and potentials in the future. J Gastrointest Oncol (2017) 0.75
Cancer genome landscapes. Science (2013) 25.33
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
IgG4-related disease. N Engl J Med (2012) 15.76
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med (2010) 10.21
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut (2004) 3.35
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology (2005) 3.24
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology (2009) 3.03
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut (2012) 2.91
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc (2010) 2.67
Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene (2006) 2.65
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc (2012) 2.40
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Outcomes after curative resections of cholangiocarcinoma. Arch Surg (1993) 2.26
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest (2012) 2.26
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol (2013) 2.23
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology (2000) 2.21
Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc (2005) 2.18
Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc (2006) 2.11
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology (2009) 2.10
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer (2007) 2.09
Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc (1998) 2.05
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg (2001) 1.93
Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc (2010) 1.91
Bile duct cysts in adults. Br J Surg (2004) 1.89
Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol (1996) 1.86
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development (2010) 1.78
Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg (2004) 1.77
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control (2001) 1.74
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett (2012) 1.73
Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci (2011) 1.71
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology (2013) 1.65
High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol (2008) 1.64
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol (2011) 1.61
Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg (2003) 1.59
Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc (1988) 1.59
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol (2008) 1.58
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int (2013) 1.57
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol (2008) 1.54
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology (2011) 1.52
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology (2011) 1.49
Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci (2004) 1.48
Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer (2007) 1.46
Serum and bile markers for cholangiocarcinoma. Semin Liver Dis (2004) 1.46
Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer (2005) 1.45
Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int (2006) 1.45
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol (2002) 1.40
Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol (2011) 1.27
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26
Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc (1999) 1.26
Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology (2011) 1.23
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol (2013) 1.23
Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol (2011) 1.22
The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res (2009) 1.21
Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer (2011) 1.20
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res (2012) 1.19
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer (2010) 1.18
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17
Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.16
Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol (2009) 1.15
Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol (2008) 1.12
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol (2012) 1.10
Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol (2012) 1.09